-
Inhibitory concentration of the compound against 5-lipoxygenase in rat RBL-1 cells
-
Inhibitory concentration of the compound against Prostaglandin H2 synthase 1 (PGHS-1) from ram seminal vesicle
-
In vivo inhibition of LPS-induced TNF production in mice 50 mg/Kg.
-
In vitro inhibitory concentration against radioligand [3H]-SB-202,190 binding to CSBP kinase in human monocytic cell 0
-
Antiprotozoal activity against 20 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation o0
-
Antiprotozoal activity against 20 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation o0
-
Antiprotozoal activity activity against Encephalitozoon cuniculi infected in CD8 knockout CJ57BL/6 mouse mouse surviv0
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation 0
-
Antiprotozoal activity against 1000 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation0
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse mouse survival at 60 mg/k0
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation 0
-
Toxicity in CBA/J mouse at 30 mg/kg, ip
-
Antiprotozoal activity against 5 MOI Toxoplasma gondii Me49 tachyzoites infected in confluent HFF assessed as inhibit0
-
Antiprotozoal activity against 5 MOI SB203580-resistant Toxoplasma gondii SBRMe49-2 tachyzoites infected in confluent0
-
Toxicity in CBA/J mouse at 50 mg/kg, po
-
Antiprotozoal activity against 2000Toxoplasma gondii RH tachyzoites infected 30 days after initial 100 parasite infec0
-
Inhibition of TNF-alpha production in rat joint after oral administration at 3 mg/Kg
-
Antiprotozoal activity against 2000Toxoplasma gondii RH tachyzoites infected 30 days after initial 20 parasite infect0
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation 0
-
Inhibition of human recombinant p38alpha assessed as [gamma33P]ATP utilization by microplate scintillation counting
-
In vivo threshold minimum effective dose for inhibition of bone erosion and cartilage destruction in rat after oral b0
-
Toxicity in CBA/J mouse assessed as occasional and transient fur ruffling at 60 mg/kg, ip
-
Antiprotozoal activity against 1000 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation0
-
Inhibition of Toxoplasma gondii recombinant MAPK1 expressed in Escherichia coli
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse mouse survival at 60 mg/k0
-
In vivo threshold minimum effective dose for inhibition of rat paw-swelling after oral bid dosing for 14 days
-
Toxicity in CBA/J mouse at 17 mg/kg, po
-
Antiprotozoal activity against 2000Toxoplasma gondii RH tachyzoites infected 30 days after initial 20 parasite infect0
-
Antiprotozoal activity against 1000 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation0
-
Antiprotozoal activity against 2000Toxoplasma gondii RH tachyzoites infected 30 days after initial 100 parasite infec0
-
Antiprotozoal activity against 1000 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation0
-
Antiprotozoal activity against 20 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation o0
-
Antiprotozoal activity against 1 MOI Toxoplasma gondii RH tachyzoites infected in confluent HFF assessed as inhibitio0
-
Antiprotozoal activity against 20 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation o0
-
Antiprotozoal activity against 1000 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse assessed as prolongation0
-
Antiprotozoal activity activity against Encephalitozoon cuniculi infected in CD8 knockout CJ57BL/6 mouse assessed as 0
-
Antiprotozoal activity against 100 Toxoplasma gondii RH tachyzoites infected in CBA/J mouse mouse survival at 60 mg/k0
-
Inhibition of human ABL1 at 20 uM by FRET assay
-
Inhibition of human INSR at 20 uM by FRET assay
-
Inhibition of human IRAK4 at 20 uM by FRET assay
-
Inhibition of human MAP4K4 at 20 uM by FRET assay
-
Inhibition of human MAPKAPK2 at 20 uM by FRET assay
-
Inhibition of human p70S6K at 20 uM by FRET assay
-
Inhibition of human CDK1/cyclin B at 20 uM by FRET assay
-
Inhibition of human FGFR1 at 20 uM by FRET assay
-
Inhibition of human PAK4 at 20 uM by FRET assay
-
Inhibition of human EPHA2 at 20 uM by FRET assay
-
Inhibition of p38alpha by FRET assay
-
Inhibition of human SRC at 20 uM by FRET assay
-
Inhibition of human JAK3 at 20 uM by FRET assay
-
Inhibition of human BTK at 20 uM by FRET assay
-
Inhibition of human PIM1 at 20 uM by FRET assay
-
Inhibition of human MARK2 at 20 uM by FRET assay
-
Inhibition of human AMPK subunitG1 at 20 uM by FRET assay
-
Inhibition of human AMPK subunitA1 at 20 uM by FRET assay
-
Inhibition of human JNK2 at 20 uM by FRET assay
-
Inhibition of CYP2D6 at 10 uM
-
Inhibition of human RPS6KA3 at 20 uM by FRET assay
-
Selectivity ratio for IC50 of p38alpha to IC50 of p38beta
-
Inhibition of human CK1gamma2 at 20 uM by FRET assay
-
Inhibition of human IKKbeta at 20 uM by FRET assay
-
Inhibition of human CHK1 at 20 uM by FRET assay
-
Inhibition of human PHKG2 at 20 uM by FRET assay
-
Inhibition of human ALK4 at 20 uM by FRET assay
-
Inhibition of human MEK1 at 20 uM by FRET assay
-
Inhibition of human LCK at 20 uM by FRET assay
-
Inhibition of p38alpha at 10 uM by FRET assay
-
Inhibition of human PDGFRbeta at 20 uM by FRET assay
-
Inhibition of human PLK1 at 20 uM by FRET assay
-
Inhibition of human EGFR at 20 uM by FRET assay
-
Inhibition of human KIT at 20 uM by FRET assay
-
Inhibition of human ROCK1 at 20 uM by FRET assay
-
Inhibition of human KDR at 20 uM by FRET assay
-
Inhibition of human NTRK1 at 20 uM by FRET assay
-
Inhibition of human SYK at 20 uM by FRET assay
-
Inhibition of human FLT3 at 20 uM by FRET assay
-
Inhibition of human PRKACA at 20 uM by FRET assay
-
Inhibition of human IGF1R at 20 uM by FRET assay
-
Inhibition of human MAP4K4 by FRET assay
-
Inhibition of human NEK1 at 20 uM by FRET assay
-
Inhibition of human RET at 20 uM by FRET assay
-
Inhibition of human CK2alpha1 at 20 uM by FRET assay
-
Inhibition of human Aurora A at 20 uM by FRET assay
-
Inhibition of human GSK3beta at 20 uM by FRET assay
-
Inhibition of p38beta by FRET assay
-
Inhibition of human MET at 20 uM by FRET assay
-
Inhibition of human RAF1 at 20 uM by FRET assay
-
Inhibition of human p38gamma at 20 uM by FRET assay
-
Inhibition of human FRAP1 at 20 uM by FRET assay
-
Inhibition of human TEK at 20 uM by FRET assay
-
Inhibition of human ERBB2 at 20 uM by FRET assay
-
Inhibition of human AKT1 at 20 uM by FRET assay
-
Inhibition of human DYRK3 at 20 uM by FRET assay
-
Inhibition of human ERK2 at 20 uM by FRET assay
-
Inhibition of human p38delta at 20 uM by FRET assay
-
Inhibition of human AMPK subunitB1 at 20 uM by FRET assay
-
Inhibition of human JNK1 at 20 uM by FRET assay
-
Inhibition of human PKCbeta1 at 20 uM by FRET assay
-
Inhibition of JNK3 by non-radioactive immunosorbent assay
-
Inhibition of p38 kinase
- Click here to view all the results.